Clinical Trial Update: BE Study of Albuterol Sulfate Inhalation Aerosol 90 mcg Per Actuation in Patients With Stable Mild Asthma [Phase 3]

View source ↗

Summary

Cipla Ltd’s Albuterol Sulfate Inhalation Aerosol (90 mcg/actuation) completed a Phase 3 bioequivalence study in adults with stable mild asthma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Albuterol Sulfate Inhalation Aerosol 90 mcg/actuation (albuterol sulfate inhalation aerosol)

Snippet

Sponsor: Cipla Ltd. | Conditions: Bronchial Asthma | Phase 3 | Status: COMPLETED